Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict frailty in serious illness? a large study investigates

NCT ID NCT07740239

Knowledge-focused Sponsor: Tampere University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study looks at why some older adults with serious conditions like cancer or fractures become vulnerable or frail. Researchers will follow about 1500 patients to find out how common different causes of vulnerability are and how they affect outcomes like survival and quality of life. The goal is to see if current screening tools work well for these patients and to improve how we detect and address vulnerability.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This could lead to better ways to identify and address vulnerability in older patients with serious illnesses, potentially improving their quality of life and survival.
What could go wrong
As an observational study, it cannot prove cause and effect. The findings may not apply to all patients or settings, and the study's large scope may introduce complexities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,050 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Patients with local, locally advanced and metastatic prostate cancer (n=300) * Patients with locally advanced and metastatic lung cancer (n=300) * Patients with brain metastasis (n=300) * Patients with chronic subdural hematoma (n=300) * Patients receiving high-dose chemotherapy and stem cell transplantion

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Suspected or diagnosed disease * ≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old * Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line * Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line * Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment * Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization Exclusion Criteria: * Not willing or unable to give written consent * Patient not deemed suitable for the study by the researcher approaching the patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer Hematoma, Subdural, Chronic hip fracture lung cancer lung neoplasm metastatic malignant neoplasm in the brain prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastasis Chronic subdural hematoma Lung cancer Pelvic fracture Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tampere University Hospital

    RECRUITING

    Tampere, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.